|Bid||19.63 x 84100|
|Ask||19.65 x 12400|
|Day's Range||19.53 - 20.20|
|52 Week Range||13.16 - 44.67|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||41.79|
|Earnings Date||Aug 21, 2022 - Aug 26, 2022|
|Forward Dividend & Yield||0.03 (0.12%)|
|Ex-Dividend Date||Sep 02, 2021|
|1y Target Est||26.31|
Subscribe to Yahoo Finance Plus to view Fair Value for CUV.AX
Does the August share price for Clinuvel Pharmaceuticals Limited ( ASX:CUV ) reflect what it's really worth? Today, we...
The big shareholder groups in Clinuvel Pharmaceuticals Limited ( ASX:CUV ) have power over the company. Insiders often...
Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide Vitiligo repigmentation in CLINUVEL's CUV102 study Initial clinical studies of afamelanotide showed the drug could repigment skin. This patient received four afamelanotide implants and NB-UVB light therapy over six months, largely repigmenting lesions on their eyelids. Images taken at days 0 and 171 of CUV102 study, courtesy of the study investigator. MELBOURNE, Australia, May 09, 2022 (GLO